Bronx, New York, June 27, 2023 /PRNewswire/ – SYBLEU INC (OTC PINK: SYBE), a biotechnology company focused on human and animal health, medical devices and clinical diagnostics, is preparing to begin advancing small molecule medicines for animal and human health.
Because Sybleu has developed a corporate strategy focused on bringing technologies to market by acquiring intellectual property and forming strategic partnerships, the company has been carefully exploring licensing opportunities while building its portfolio.
The company has identified technology owned by DYO Biotechnologies, Pty, Ltd, which specializes in artificial intelligence and machine learning and is currently used to develop drugs in clinical trials.
Specifically, this technology includes an artificial intelligence/machine learning engine designed to use the structures of existing chemical libraries in an integrated model to predict highly specific and sensitive novel chemical structures for molecular targets. Any future small molecule drugs that Sybleu licenses or develops could be rapidly improved and move forward in the development process using this intellectual property.
Pursuant to the license agreement, Sybleu will have exclusive worldwide rights to the intellectual property and will own any intellectual property that DYO contracts to develop. In addition, Sybleu will have the right to sublicense the Technology.
“As the company completes construction for an exciting period, we want to focus on using new technologies to bring our products to market more efficiently and quickly,” he said. Joseph VineyCEO of Siblu. “Using this advanced AI/ML technology could provide significant benefits to our future small molecule programs and perhaps to other companies developing small molecules.”
About Sybleu Inc.
SYBLEU INC (OTC PINK: SYBE) is a biotechnology company focused on human and animal health, medical devices and clinical diagnostics. Our strategy is to acquire intellectual property and create strategic partnerships to bring technologies to market. SYBLEU Inc. He is currently exploring opportunities in veterinary medicine, diagnostics and medical devices. More information on SYBLEU is available at http://www.sybleu.com.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results may differ materially from those expressed, projected or implied in the forward-looking statements. Risks and uncertainties affecting forward-looking statements include the effects of government regulation, competition and other material risks.
Contact Address:
To Mr. Joseph G. Viney
Chairman and CEO
Phone: +1.800.807.4631
Email: [email protected]Com
Source: Sybleu Inc.
[ad_2]